AInvest★★★★★3-DAY FREE
Catch pre-market movers with AI signals.
Claim Trial
Progyny up 6% on insider buys
ParAinvest
vendredi 27 décembre 2024 08:44 ET1 min de lecture
PGNY--
One of the most significant purchases was made by Ali Motamed, the Chief Investment Officer of Invenomic Capital Management. Motamed acquired 1,760,706 shares of PGNY, worth approximately $29.5 million [2]. This transaction represented a sizable 1.62% increase in Motamed's total holdings of the company [2].
Another notable insider purchase was made by Philip Timon, the Founder and Chief Investment Officer of Owls Nest Partners. Timon sold 1,523,147 shares of PGNY but simultaneously purchased 1,523,147 new shares [2]. Although this transaction resulted in no net change to Timon's overall holdings, it demonstrated his confidence in the company's future prospects.
The hedge fund with the largest stake in PGNY is Farallon Capital, managed by Thomas Steyer. Steyer reduced his holdings by selling 931,307 shares of the company, worth around $15.6 million [2]. Despite this sale, Steyer still holds a significant 0.07% stake in PGNY [2].
Steve Cohen, the Founder and Chief Executive Officer of Point72 Asset Management, also made a notable purchase of 789,418 shares of PGNY, worth approximately $13.2 million [2]. This transaction represented a substantial 228% increase in Cohen's total holdings of the company [2].
Israel Englander, the Founder and Chief Investment Officer of Millennium Management, acquired 563,535 shares of PGNY, worth around $9.4 million [2]. This purchase represented a 6% increase in Englander's overall holdings of the company [2].
The insider buying activity at PGNY is a positive sign for the company, as it demonstrates confidence from key executives and prominent investors. With a strong focus on fertility benefits, PGNY is well-positioned to capitalize on the growing demand for healthcare services in this area [1].
References:
[1] OpenInsider. Progyny Inc. Retrieved November 15, 2024, from http://openinsider.com/PGNY
[2] Insidermonkey. Progyny Inc. Hedge Fund Trading. Retrieved November 15, 2024, from https://www.insidermonkey.com/insider-trading/company/progyny+inc/1551306/
Progyny up 6% on insider buys
Progyny Inc. (PGNY), a healthcare services company specializing in fertility benefits, experienced a notable surge of 6% in its stock price on November 14, 2024 [1]. This uptick can be attributed to a series of insider purchases made by key executives and prominent hedge funds [2].One of the most significant purchases was made by Ali Motamed, the Chief Investment Officer of Invenomic Capital Management. Motamed acquired 1,760,706 shares of PGNY, worth approximately $29.5 million [2]. This transaction represented a sizable 1.62% increase in Motamed's total holdings of the company [2].
Another notable insider purchase was made by Philip Timon, the Founder and Chief Investment Officer of Owls Nest Partners. Timon sold 1,523,147 shares of PGNY but simultaneously purchased 1,523,147 new shares [2]. Although this transaction resulted in no net change to Timon's overall holdings, it demonstrated his confidence in the company's future prospects.
The hedge fund with the largest stake in PGNY is Farallon Capital, managed by Thomas Steyer. Steyer reduced his holdings by selling 931,307 shares of the company, worth around $15.6 million [2]. Despite this sale, Steyer still holds a significant 0.07% stake in PGNY [2].
Steve Cohen, the Founder and Chief Executive Officer of Point72 Asset Management, also made a notable purchase of 789,418 shares of PGNY, worth approximately $13.2 million [2]. This transaction represented a substantial 228% increase in Cohen's total holdings of the company [2].
Israel Englander, the Founder and Chief Investment Officer of Millennium Management, acquired 563,535 shares of PGNY, worth around $9.4 million [2]. This purchase represented a 6% increase in Englander's overall holdings of the company [2].
The insider buying activity at PGNY is a positive sign for the company, as it demonstrates confidence from key executives and prominent investors. With a strong focus on fertility benefits, PGNY is well-positioned to capitalize on the growing demand for healthcare services in this area [1].
References:
[1] OpenInsider. Progyny Inc. Retrieved November 15, 2024, from http://openinsider.com/PGNY
[2] Insidermonkey. Progyny Inc. Hedge Fund Trading. Retrieved November 15, 2024, from https://www.insidermonkey.com/insider-trading/company/progyny+inc/1551306/

Divulgation éditoriale et transparence sur l'IA : Ainvest News s'appuie sur une technologie avancée de grands modèles de langage (LLM) pour synthétiser et analyser les données de marché en temps réel. Afin de garantir les plus hauts standards d'intégrité, chaque article suit un processus rigoureux de vérification « humain dans la boucle ».
L'IA assiste au traitement des données et à la rédaction initiale, mais un membre professionnel de l'équipe éditoriale d'Ainvest examine, vérifie et approuve de manière indépendante l'ensemble du contenu pour en assurer l'exactitude et la conformité aux normes éditoriales d'Ainvest Fintech Inc. Cette supervision humaine vise à limiter les hallucinations de l'IA et à garantir le contexte financier.
Mise en garde relative aux investissements : ce contenu est fourni à titre informatif uniquement et ne constitue pas un conseil professionnel en investissement, en droit ou en finance. Les marchés comportent des risques inhérents. Les utilisateurs sont invités à mener leurs propres recherches ou à consulter un conseiller financier agréé avant toute décision. Ainvest Fintech Inc. décline toute responsabilité quant aux actions entreprises sur la base de ces informations. Vous avez repéré une erreur ?Signaler un problème



Commentaires
Pas encore de commentaires